Hyderabad, India and Princeton, NJ, USA. July 30, 2019 — Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE:
DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the
launch of Pregabalin Capsules a therapeutic equivalent generic version of Lyrica® (pregabalin) Capsules approved by
the U.S. Food and Drug Administration (USFDA).
The Lyrica® (pregabalin) Capsules brand had U.S. sales of approximately $5,462 million MAT for the most recent
twelve months ending in May 2019 according to IQVIA Health*.
Dr. Reddy’s Pregabalin Capsules are available in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300
mg capsules in bottle count sizes of 90. This is also a controlled substance schedule V product.
Lyrica® is a trademark of C.P. PHARMACEUTICALS INTERNATIONAL C.V.
*IQVIA Retail and Non-Retail MAT May 2019.
RDY-0719-257
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major
markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
